文献速递胸部肿瘤

循环肿瘤细胞在局限期小细胞肺癌中的预后价值:CONVERT随机对照试验分析

Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
PubMed 文献 · Ann Oncol · 2019-01-01

该研究在CONVERT III期随机试验入组的75例局限期小细胞肺癌患者中,用CellSearch检测基线循环肿瘤细胞(CTC)。CTC在60%(45/75)患者中检出,2、15、50个CTC阈值均与无进展生存和总生存显著相关;以15个CTC为最佳阈值,<15 vs ≥15个CTC的中位总生存为26.7 vs 5.9个月(P=0.001),≥15个CTC独立预测≤2年生存。

要点

  • 75例局限期小细胞肺癌患者基线CTC检出率为60%(45/75),范围0-3750。
  • 2、15、50个CTC阈值均与PFS和OS显著相关,最佳阈值为15个CTC。
  • <15 vs ≥15个CTC的中位OS为26.7 vs 5.9个月(P=0.001),≥15个CTC独立预测≤2年生存。

核心结论

  • 在局限期小细胞肺癌人群中,基线CTC计数在2、15、50个阈值均具预后价值,≥15个CTC与更差PFS和OS独立相关并预测≤2年生存。
  • 作者认为这些结果可能改善未来临床试验设计中的疾病分层并辅助临床决策。

研究设计与样本

  • III期随机CONVERT试验(每日一次 vs 每日两次同步化放疗)的计划探索性分析。
  • 入组75例局限期小细胞肺癌患者,基线血样用CellSearch检测CTC。
  • 采用标准统计方法分析CTC与临床因素的相关性,用log-rank检验和Cox回归分析2、15、50个CTC阈值与PFS和OS的关联,并确立最佳CTC计数阈值。

主要发现

  • CTC在60%(45/75)患者中检出,范围0-3750。
  • 2、15、50个CTC阈值均与PFS和OS显著相关,最佳阈值为15个CTC,定义「有利」和「不利」预后风险组。
  • <15 vs ≥15个CTC的中位OS为26.7 vs 5.9个月(P=0.001)。
  • 基线≥15个CTC独立预测70%患者≤1年生存和100%患者≤2年生存。

关键数值与推荐

  • CTC计数阈值:2、15、50个CTC均与PFS和OS显著相关。
  • 最佳CTC计数阈值为15个CTC,据此划分「有利」与「不利」预后风险组。
  • <15 vs ≥15个CTC的中位OS为26.7 vs 5.9个月(P=0.001)。

临床怎么用

  • 作者认为基线CTC计数结果可能改善未来临床试验设计中的疾病分层并辅助临床决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical significance of circulating tumour cells (CTCs) in limited-stage small-cell lung cancer (LS-SCLC) is not well defined. We report a planned exploratory analysis of the prevalence and prognostic value of CTCs in LS-SCLC patients enrolled within the phase III randomised CONVERT (concurrent once-daily versus twice-daily chemoradiotherapy) trial. PATIENTS AND METHODS: Baseline blood samples were enumerated for CTCs using CellSearch in 75 patients with LS-SCLC who were enrolled in the CONVERT trial and randomised between twice- and once-daily concurrent chemoradiation. Standard statistical methods were used for correlations of CTCs with clinical factors. Log-rank test and Cox regression analyses were applied to establish the associations of 2, 15 and 50 CTC thresholds with progression-free survival (PFS) and overall survival (OS). An optimal CTC count threshold for LS-SCLC was established. RESULTS: CTCs were detected in 60% (45/75) of patients (range 0-3750). CTC count thresholds of 2, 15 and 50 CTCs all significantly correlate with PFS and OS. An optimal CTC count threshold in LS-SCLC was established at 15 CTCs, defining 'favourable' and 'unfavourable' prognostic risk groups. The median OS in <15 versus ≥15 CTCs was 26.7 versus 5.9 m (P = 0.001). The presence of ≥15 CTCs at baseline independently predicted ≤1 year survival in 70% and ≤2 years survival in 100% of patients. CONCLUSION: We report the prognostic value of baseline CTC count in an exclusive LS-SCLC population at thresholds of 2, 15 and 50 CTCs. Specific to LS-SCLC, ≥15 CTCs was associated with worse PFS and OS independent of all other factors and predicted ≤2 years survival. These results may improve disease stratification in future clinical trial designs and aid clinical decision making. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00433563.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Tay RY, Fernández-Gutiérrez F, Foy V, et al. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial. Ann Oncol. 2019. PMID: 31020334. doi:10.1093/annonc/mdz122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。